Clostridium perfringens alpha toxin proteins

US7982006B2 · kind B2 · utility

Assignee

• DOW AGROSCIENCES LLC · US

Inventors

• William M. Ainley · Carmel, US
• Janna Mai Armstrong · Indianapolis, US
• Krishna M. Madduri · Indianapolis, US
• Donald J. Merlo · Carmel, US
• Kelley A. Smith · Lebanon, US
• Mark A. Thompson · Zionsville, US
• Steven R. Webb · Westfield, US
• Liu Y. Shen · Westfield, US

Key dates

• Filing date: Jun 23, 2010
• Grant date: Jul 19, 2011
• Expiry date: Jun 23, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K2039/55577
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention pertains in part to the development of a vaccine for poultry against necrotic enteritis (NE). The vaccine utilizes a protective antigen that is a mutated, full-length, non-toxic Clostridium perfringens (Cp) α-toxin protein (Mcpa). Utility of this vaccine was demonstrated by reduction of lesion severity in NE challenge trails, for example. Also disclosed herein are novel approaches for producing this vaccine in significant quantities. One exemplified approach involves producing NE vaccine (mutated alpha toxin) in bacterial expression systems, preferably utilizing the Pseudomonas fluorescens system, for commercial use in controlling NE in the poultry industry. The subject vaccines can be administered preferably to chickens in several different ways. A novel, Type VI alpha toxin from chicken isolates of Cp is also disclosed.